BERTIN-TECHNOLOGIES
Bertin Technologies , a subsidiary of CNIM Group , has been chosen by the authorities of Switzerland and by the European Commission – on behalf of Armenia – to provide tailored radiation monitoring systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190516005320/en/
These new contracts reassert Bertin’s strong expertise in Environmental Radiation Monitoring Systems (ERMS) and demonstrate its flexibility to meet specific requirements.
The Swiss authorities chose Bertin for the renewal of their MADUK 1 and NADAM 2 radiation monitoring networks . Bertin Technologies also won a tender for ANRA (Armenian Nuclear Regulatory Authority) , within the framework of a contract funded by the European Union , to provide equipment and services in order to improve radiation monitoring near and around the Metsamor nuclear power plant3 in Armenia .
Bertin’s solutions perform the surveillance of radioactivity in air, soil and water around nuclear facilities or for nationwide monitoring purposes to help ensuring human safety .
They include a broad range of sensors, including gamma dose measurements , air monitoring , and spectroscopic analysis for radionuclide identification . Collected data is transmitted through secured and emergency proof channels including radio, 4G or satellite. A central data management system allows managing, analyzing and visualizing the situation in real time.
Backed by the in-depth know-how of Saphymo (acquired in 2015), Bertin has developed and optimized cutting-edge instrumentation equipment for the detection and monitoring of ionizing radiation, which comply with the strictest international requirements.
These contracts showcase the expertise of Bertin’s teams in the field of radiological monitoring
1
automatic dose-rate monitoring network operated by the Federal
Nuclear Safety Inspectorate (ENSI)
set up in 1993 in the vicinity of
nuclear facilities
2
nationwide emergency monitoring
system for gamma radiation operated
by NAZ
, the federal center of expertise for exceptional incidents, a
division of the Federal Office for Civil Protection.
3
Project funded by European Union EuropeAid/139508/DH/SUP/AM
ProjectA3.01/15A
ABOUT BERTIN TECHNOLOGIES
Bertin Technologies relies on its long history of innovation to develop, produce and market innovative systems and equipment worldwide. Among its 620 employees, there are 2/3 engineers and high-level managers. The company is active worldwide and its turnover amounts to nearly 100 million euros in 2018.
Its instrumentation business unit is dedicated to innovative measurement and sampling for the key worldwide markets of Nuclear, Defense, Security & Life Sciences.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005320/en/
Contact:
Press Contact
Frédérique Vigezzi frederique.vigezzi@gootenberg.fr Tel : + 33 1 43 59 29 84
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press release
Announcement of Enry’s Island AdVentures: the world’s first video game to learn how to launch and scale startups, focused on democratizing innovation for “Long Tail Users” Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press release
Part of the Digital Morocco 2030 strategy, 500 Global has been selected to support the Startup Venture Building (Startup VB) initiative. 500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to streng
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press release
New capital accelerates Neural Concept’s ability to deliver transformative technologies and enterprise-wide AI impact across advanced industrial workflows.Platform delivers CAD-native, physics-aware AI and deep reasoning for engineering, saving customers $50 million annually, reducing late-stage redesigns by 30-50% and accelerating time to market by up to two years.The company has generated a fourfold increase in enterprise revenue over the past 18 months.More than 50 global companies are actively relying on the platform, including General Motors, General Electric Vernova, Leonardo Aerospace, Eaton, Safran, Renault Group and multiple Formula 1 teams. Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special?MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
